MYCN and neuroblastoma: As shown in Figure 5D, after treatment with NBT, the expression levels of MRP1 and MYCN decreased in A549/ADR cells in a time-dependent manner, consistent with the previous report that MRP1 is a downstream transcriptional target of MYCN in neuroblastomas [12].